QUESTIONS ASKED FREQUENTLY BY PATIENTS
What is the AMBLor test?
I have just been diagnosed with a melanoma, how can I get the AMBLor test?
In future, we would expect that the local histopathology team at your treatment Hospital will send sections of your melanoma specimen for analysis of the AMBLor test at our facility within Newcastle University.
How can I be sure that the test is accurate?
Where and how was the test developed?
Prof Lovat’s team received an award for £100,000 to develop the AMBLor test from the Melanoma Focus Group which was able to kickstart the project https://melanomafocus.com/
How do I find out if the test is appropriate for me?
Although most of our data to date has been in AJCC stage I a melanomas, we feel that it is likely to be of value in assessing all primary melanoma samples as long as the tumours are not ulcerated.
I have been told my melanoma is ulcerated; what does this mean?
As the AMBLor test reveals changes of proteins within the epidermis, if the tumour is ulcerated these proteins cannot be visualised which makes the test inaccurate in ulcerated tumours. For this reason, the AMBLor test cannot be undertaken in ulcerated melanomas.
Can I only have the test at diagnosis of my melanoma?
Can I ask for the AMBLor test to be done directly from the company?
If the test says that I am “low risk”, what is the chance it could be wrong?
My doctor wants me to have regular follow-ups, but if the test says I’m low risk would this still happen?
The AMLo team are in discussion with the National Institute of Clinical Excellence (NICE) to see how we can make this test available for all patients diagnosed with melanoma in the UK. As part of this, we are also undertaking a National Institute of Health Research sponsored health technology assessment looking at the current evidence base for follow-up regimes in patients diagnosed with stage I melanoma. This will allow us to design evidence-based follow-up regimes for the future, as well as assessing what role the AMBLor test may have in future treatment decisions. It may be, if a patient has a “low risk” AMBLor result, that they undergo a less rigorous follow-up regime, but this will be decided on by the expert advisory groups who produce the melanoma guidelines for the UK.
Do I need to have a further procedure undertaken for the AMBLor test to be undertaken?
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address: Newcastle University, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter